14,607 Shares in Bristol Myers Squibb Company $BMY Acquired by Sanders Morris Harris LLC

Sanders Morris Harris LLC acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 14,607 shares of the biopharmaceutical company’s stock, valued at approximately $913,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BMY. Adirondack Trust Co. boosted its position in Bristol Myers Squibb by 1.1% during the 3rd quarter. Adirondack Trust Co. now owns 19,933 shares of the biopharmaceutical company’s stock valued at $1,244,000 after buying an additional 222 shares during the period. Lodestone Wealth Management LLC grew its holdings in Bristol Myers Squibb by 15.3% in the 3rd quarter. Lodestone Wealth Management LLC now owns 1,885 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 250 shares during the last quarter. Seelaus Asset Management LLC increased its position in shares of Bristol Myers Squibb by 13.1% in the third quarter. Seelaus Asset Management LLC now owns 10,783 shares of the biopharmaceutical company’s stock valued at $673,000 after acquiring an additional 1,253 shares during the period. Stone Summit Wealth LLC increased its position in shares of Bristol Myers Squibb by 11.3% in the third quarter. Stone Summit Wealth LLC now owns 27,604 shares of the biopharmaceutical company’s stock valued at $1,722,000 after acquiring an additional 2,796 shares during the period. Finally, Salem Investment Counselors Inc. raised its stake in shares of Bristol Myers Squibb by 6.5% during the third quarter. Salem Investment Counselors Inc. now owns 22,700 shares of the biopharmaceutical company’s stock valued at $1,416,000 after acquiring an additional 1,390 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 4.7%

Shares of BMY opened at $59.34 on Thursday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The firm’s 50-day moving average price is $63.72 and its 200-day moving average price is $60.28. The firm has a market capitalization of $121.22 billion, a price-to-earnings ratio of 8.71, a PEG ratio of 0.28 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb’s revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.70 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on BMY shares. Leerink Partners lowered shares of Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $73.00 to $59.00 in a report on Monday, October 5th. TD Cowen started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating on the stock. Weiss Ratings raised Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Finally, Argus upgraded Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective on the stock in a research report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $64.88.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Pipeline progress provided the main catalyst. Bristol Myers reported favorable Phase 3 results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, including improved progression-free survival. The data may support upcoming regulatory discussions and strengthen the company’s growth outlook as older blockbuster drugs face competitive pressure. What Could Bristol Myers Squibb BMY Two Phase 3 Wins Change?
• Positive Sentiment: Analyst support remains a tailwind. Truist Financial maintained its Buy rating on BMY, signaling confidence in the company’s pipeline and valuation. Bristol Myers’ relatively low earnings multiple and sizeable dividend yield may also attract income-oriented investors. Truist Financial Sticks to Its Buy Rating for Bristol Myers Squibb
• Neutral Sentiment: Admilparant results were characterized inconsistently. Reports described the Phase 3 idiopathic pulmonary fibrosis data as either positive or mixed, with favorable efficacy and safety observations but some limitations that could affect regulatory expectations. The conflicting interpretation makes the drug a potential opportunity but not yet a clear near-term catalyst. BMY Reports Mixed Phase III Trial Results
• Neutral Sentiment: Investor attention is elevated ahead of quarterly earnings. BMY is scheduled to report third-quarter results later this month, with analysts expecting a single-digit decline in earnings. Recent trial news and the stock’s strong longer-term performance have increased focus on whether results and guidance can support the valuation. Bristol Myers Squibb Quarterly Earnings Preview
• Negative Sentiment: Wells Fargo reduced its price target from $65 to $60 and kept an Equal Weight rating. The lower target reflects limited perceived upside and highlights ongoing concerns about earnings growth, patent-related pressure and the need for newer medicines to replace aging blockbusters. Wells Fargo Lowers Bristol Myers Squibb Price Target

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.05% of the stock is currently owned by insiders.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.